Literature DB >> 34202370

Chelator-Free/Chelator-Mediated Radiolabeling of Colloidally Stabilized Iron Oxide Nanoparticles for Biomedical Imaging.

Sofia Papadopoulou1,2, Argiris Kolokithas-Ntoukas3,4, Evangelia-Alexandra Salvanou1,3, Anastasios Gaitanis5, Stavros Xanthopoulos1, Konstantinos Avgoustakis3, Maria Gazouli6, Maria Paravatou-Petsotas1, Charalampos Tsoukalas1, Aristides Bakandritsos7,8, Penelope Bouziotis1.   

Abstract

The aim of this study was to develop a bioimaging probe based on magnetic iron oxide nanoparticles (MIONs) surface functionalized with the copolymer (p(MAA-g-EGMA)), which were radiolabeled with the positron emitter Gallium-68. The synthesis of the hybrid MIONs was realized by hydrolytic condensation of a single ferrous precursor in the presence of the copolymer. The synthesized MagP MIONs displayed an average Dh of 87 nm, suitable for passive targeting of cancerous tissues through the enhanced permeation and retention (EPR) effect after intravenous administration, while their particularly high magnetic content ascribes strong magnetic properties to the colloids. Two different approaches were explored to develop MIONs radiolabeled with 68Ga: the chelator-mediated approach, where the chelating agent NODAGA-NHS was conjugated onto the MIONs (MagP-NODAGA) to form a chelate complex with 68Ga, and the chelator-free approach, where 68Ga was directly incorporated onto the MIONs (MagP). Both groups of NPs showed highly efficient radiolabeling with 68Ga, forming constructs which were stable with time, and in the presence of PBS and human serum. Ex vivo biodistribution studies of [68Ga]Ga- MIONs showed high accumulation in the mononuclear phagocyte system (MPS) organs and satisfactory blood retention with time. In vivo PET imaging with [68Ga]Ga-MagP MIONs was in accordance with the ex vivo biodistribution results. Finally, the MIONs showed low toxicity against 4T1 breast cancer cells. These detailed studies established that [68Ga]Ga- MIONs exhibit potential for application as tracers for early cancer detection.

Entities:  

Keywords:  Gallium-68; MTT; PET; biodistribution; iron oxide nanoparticles; radiolabeling

Year:  2021        PMID: 34202370     DOI: 10.3390/nano11071677

Source DB:  PubMed          Journal:  Nanomaterials (Basel)        ISSN: 2079-4991            Impact factor:   5.076


  41 in total

Review 1.  Theranostic applications of nanoparticles in cancer.

Authors:  Naveed Ahmed; Hatem Fessi; Abdelhamid Elaissari
Journal:  Drug Discov Today       Date:  2012-03-30       Impact factor: 7.851

2.  Multimodality PET/MRI agents targeted to activated macrophages.

Authors:  Chuqiao Tu; Thomas S C Ng; Russell E Jacobs; Angelique Y Louie
Journal:  J Biol Inorg Chem       Date:  2013-10-29       Impact factor: 3.358

3.  Development of Ga-68 labeled, biotinylated thiosemicarbazone dextran-coated iron oxide nanoparticles as multimodal PET/MRI probe.

Authors:  Nazila Gholipour; Mehdi Akhlaghi; Amin Mokhtari Kheirabadi; Parham Geramifar; Davood Beiki
Journal:  Int J Biol Macromol       Date:  2020-01-23       Impact factor: 6.953

Review 4.  Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.

Authors:  Daniel Bobo; Kye J Robinson; Jiaul Islam; Kristofer J Thurecht; Simon R Corrie
Journal:  Pharm Res       Date:  2016-06-14       Impact factor: 4.200

Review 5.  The mechanism of 67Ga localization in malignant disease.

Authors:  R E Weiner
Journal:  Nucl Med Biol       Date:  1996-08       Impact factor: 2.408

Review 6.  Surface engineering of iron oxide nanoparticles for targeted cancer therapy.

Authors:  Forrest M Kievit; Miqin Zhang
Journal:  Acc Chem Res       Date:  2011-04-29       Impact factor: 22.384

7.  A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Therapeutic Isotopes.

Authors:  Yaser H Gholami; Lee Josephson; Eman A Akam; Peter Caravan; Moses Q Wilks; Xiang-Zuo Pan; Richard Maschmeyer; Aleksandra Kolnick; Georges El Fakhri; Marc D Normandin; Zdenka Kuncic; Hushan Yuan
Journal:  Int J Nanomedicine       Date:  2020-01-07

8.  (⁹⁹m)Tc-bisphosphonate-iron oxide nanoparticle conjugates for dual-modality biomedical imaging.

Authors:  Rafael Torres Martin de Rosales; Richard Tavaré; Arnaud Glaria; Gopal Varma; Andrea Protti; Philip J Blower
Journal:  Bioconjug Chem       Date:  2011-02-21       Impact factor: 4.774

9.  Luminescence Properties of Self-Aggregating TbIII-DOTA-Functionalized Calix[4]arenes.

Authors:  Florian Mayer; Sriram Tiruvadi Krishnan; Daniel T Schühle; Svetlana V Eliseeva; Stéphane Petoud; Éva Tóth; Kristina Djanashvili
Journal:  Front Chem       Date:  2018-01-30       Impact factor: 5.221

10.  Accumulation and Toxicity of Superparamagnetic Iron Oxide Nanoparticles in Cells and Experimental Animals.

Authors:  Greta Jarockyte; Egle Daugelaite; Marius Stasys; Urte Statkute; Vilius Poderys; Ting-Chen Tseng; Shan-Hui Hsu; Vitalijus Karabanovas; Ricardas Rotomskis
Journal:  Int J Mol Sci       Date:  2016-08-19       Impact factor: 5.923

View more
  3 in total

Review 1.  Radiolabeling of Nanomaterials: Advantages and Challenges.

Authors:  Wanqin Dai; Junzhe Zhang; Yun Wang; Chunlei Jiao; Zhuda Song; Yuhui Ma; Yayun Ding; Zhiyong Zhang; Xiao He
Journal:  Front Toxicol       Date:  2021-12-13

2.  Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with 68Ga and 177Lu as Potential Theranostic Agents.

Authors:  Evangelia-Alexandra Salvanou; Argiris Kolokithas-Ntoukas; Christos Liolios; Stavros Xanthopoulos; Maria Paravatou-Petsotas; Charalampos Tsoukalas; Konstantinos Avgoustakis; Penelope Bouziotis
Journal:  Nanomaterials (Basel)       Date:  2022-07-20       Impact factor: 5.719

3.  99mTc-Labeled Iron Oxide Nanoparticles as Dual-Modality Contrast Agent: A Preliminary Study from Synthesis to Magnetic Resonance and Gamma-Camera Imaging in Mice Models.

Authors:  Maria-Argyro Karageorgou; Aristotelis-Nikolaos Rapsomanikis; Marija Mirković; Sanja Vranješ-Ðurić; Efstathios Stiliaris; Penelope Bouziotis; Dimosthenis Stamopoulos
Journal:  Nanomaterials (Basel)       Date:  2022-08-08       Impact factor: 5.719

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.